FDA Open To Revising Guidance On Drug-Induced Liver Injury

Good drugs can be held responsible for bad things happening to the liver if sponsors do not fully explore alternate explanations for liver toxicities that turn up in a clinical trial, cautions John Senior, associate director for science in CDER’s Office of Surveillance and Epidemiology.

More from Archive

More from Pink Sheet